Key clinical point: The rates of CIN2+ have declined in younger women since introduction of the HPV vaccine.
Major finding: The rates of vaccine-targeted CIN2+ declined from 52% in 2008 to 30% in 2016 among women aged 18-24 years.
Study details: Analysis of data from the Human Papillomavirus Vaccine Impact Monitoring Program from 2008 to 2016.
Disclosures: One author declared personal fees from Merck during the course of the study. No other conflicts of interest were declared.
McClung N et al. MMWR. 2019 Apr 19;68:337-43.
This Week's Must Reads
Must Reads in Infectious Diseases
Rapid Point of Care Test for Influenza, J Am Board Fam Med; 2019 Mar; Dale, et al
Invasive GBS Infections in Nonpregnant US Adults, JAMA Intern Med; ePub 2019 Feb 18; Francois Watkins, et al
Prescribed Opioids & Risk of CAP in Patients with HIV, JAMA Intern Med; 2019 Jan 7; Edelman, et al
Influenza Vaccination Safety During Hospitalization, Mayo Clin Proc; ePub 2019 Jan 8; Tartof, et al